TWST vs. SRPT, PCVX, QGEN, ROIV, RVMD, LNTH, LEGN, TGTX, BBIO, and AXSM
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), TG Therapeutics (TGTX), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.
Twist Bioscience vs.
Sarepta Therapeutics (NASDAQ:SRPT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.
Twist Bioscience has lower revenue, but higher earnings than Sarepta Therapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics has a net margin of 7.43% compared to Twist Bioscience's net margin of -59.76%. Sarepta Therapeutics' return on equity of 11.00% beat Twist Bioscience's return on equity.
Sarepta Therapeutics received 1364 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 75.09% of users gave Sarepta Therapeutics an outperform vote while only 59.09% of users gave Twist Bioscience an outperform vote.
In the previous week, Sarepta Therapeutics had 35 more articles in the media than Twist Bioscience. MarketBeat recorded 46 mentions for Sarepta Therapeutics and 11 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.75 beat Sarepta Therapeutics' score of -0.10 indicating that Twist Bioscience is being referred to more favorably in the news media.
Sarepta Therapeutics currently has a consensus target price of $167.41, suggesting a potential upside of 125.79%. Twist Bioscience has a consensus target price of $54.40, suggesting a potential upside of 23.79%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sarepta Therapeutics is more favorable than Twist Bioscience.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Sarepta Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500.
Summary
Sarepta Therapeutics beats Twist Bioscience on 15 of the 19 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Twist Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:TWST) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy TWST Stock Free TWST Stock Alerts